Incidence of Unresectable Cases of Cervical Cancer

• Sponsor: HOSSAM ALSUKARI (Other)
• Overall Status: Completed
• CT.gov ID: NCT05537012
• Collaborator: (none)
• Enrollment: 70
• Location: 1
• Actual Duration (Months): 42
• Patients Per Site Per Month: 1.7

Study Details

Study Description

Brief Summary

Objective : to calculate the incidence of unresectable cases of cervical cancer in gyne-oncology unit of Alexandria university hospital and to indentify its relation to pathological types, grading and lymph vascular space invasion.

Patients and methods: 70 cases of cervical cancer diagnosed by biopsy taking and histopathological examination will be included in the study, clinicoradiological staging was done to all cases to calculate the incidence of unresectable cases and to indentify its relation to pathological types, grading and lymph vascular space invasion

Condition or Disease	Intervention/Treatment	Phase
Cervical Cancer	Diagnostic Test: clinical and radiological staging, pathological types, grading and lymphovascular space invasion

Study Design

• Study Type: Observational
• Actual Enrollment: 70 participants
• Observational Model: Other
• Time Perspective: Cross-Sectional
• Official Title: Incidence of Unresectable Cases of Cervical Cancer in Gyne-oncology Unit of Alexandria University Hospital and Its Relation to Pathological Types, Grading and Lymph Vascular Space Invasion
• Actual Study Start Date: Mar 1, 2019
• Actual Primary Completion Date: Jul 31, 2022
• Actual Study Completion Date: Aug 31, 2022

Outcome Measures

Primary Outcome Measures

1. clinical and radiological staging [10 days]

   70 cases of cervical cancer diagnosed by biopsy taking and histopathological examination will be included in the study, clinicoradiological staging was done to all cases to calculate the incidence of unresectable cases and to indentify its relation to pathological types, grading and lymph vascular space invasion.

Eligibility Criteria

Criteria

• Ages Eligible for Study: N/A and Older
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• cervical cancer

Exclusion Criteria: none

-

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Hossam Hassan El Sokkary	Alexandria		Egypt

Sponsors and Collaborators

• HOSSAM ALSUKARI

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: HOSSAM ALSUKARI, Associate professor, Alexandria University
• ClinicalTrials.gov Identifier: NCT05537012
• Other Study ID Numbers: SOKKARY10
• First Posted: Sep 13, 2022
• Last Update Posted: Sep 13, 2022
• Last Verified: Sep 1, 2022

• Individual Participant Data (IPD) Sharing Statement: Undecided
• Plan to Share IPD: Undecided
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Uterine Cervical Neoplasms

Study Results

No Results Posted as of Sep 13, 2022